{
    "clinical_study": {
        "@rank": "90978", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine whether reduction of serum insulin levels by metformin increases ovulatory\n      response to clomiphene or spontaneous ovulation in obese women with polycystic ovary\n      syndrome."
        }, 
        "brief_title": "Randomized Study of the Effect of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Obese Women With Polycystic Ovary Syndrome", 
        "condition": [
            "Hyperinsulinism", 
            "Polycystic Ovary Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperinsulinism", 
                "Polycystic Ovary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, multicenter study.\n      Patients are randomized to one of two treatment arms.\n\n      Patients receive oral metformin (arm I) or oral placebo (arm II) three times daily for 8\n      weeks. All patients who do not ovulate by day 28 receive oral clomiphene citrate daily on\n      days 36-40."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Obese women with chronic anovulation due to polycystic ovary syndrome (PCOS)\n\n        Must have oligoamenorrhea and hyperandrogenemia\n\n        --Prior/Concurrent Therapy--\n\n        At least 2 months since prior standard therapy (including over the counter drugs) At least\n        2 months since prior investigational agents\n\n        --Patient Characteristics--\n\n        Hematopoietic: Hematocrit greater than 38%\n\n        Hepatic: Liver function normal No clinically significant hepatic disease\n\n        Renal: No clinically significant renal disease Creatinine less than 1.4 mg/dL No\n        proteinuria\n\n        Cardiovascular: No clinically significant cardiac disease\n\n        Pulmonary: No clinically significant pulmonary disease\n\n        Hormonal: Thyroid function normal Prolactin normal Fasting 17 alpha-hydroxy progesterone\n        less than 200 mg/dL OR No late onset adrenal hyperplasia 21 alpha-hydroxylase deficiency\n\n        Other: Not pregnant Negative pregnancy test Fertile patients must use effective\n        contraception No diabetes mellitus No clinically significant neurologic, psychiatric,\n        infectious, neoplastic, or metabolic disease No clinically significant malignant disease\n        except nonmelanomatous skin cancer At least 1 year since any prior drug abuse or\n        alcoholism"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "88", 
        "firstreceived_date": "May 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005654", 
            "org_study_id": "199/14914", 
            "secondary_id": "UVA-WSE023"
        }, 
        "intervention": [
            {
                "intervention_name": "clomiphene citrate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Clomiphene", 
                "Metformin"
            ]
        }, 
        "keyword": [
            "endocrine disorders", 
            "hyperinsulinism", 
            "polycystic ovarian syndrome", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Virginia", 
            "last_name": "William S. Evans", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005654"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Virginia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2000"
    }, 
    "geocoordinates": {}
}